The launch has helped the Eylea franchise to a rebound after U.S. sales had declined in each of the previous three quarters as it was under assault from Roche’s Vabysmo. Additionally ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal ...

REGN filed an application with the FDA for the use of the Eylea HD pre-filled syringe (PFS). A potential approval and launch are expected by mid 2025. Longer-term data in wet age-related macular ...

Even so, the impact of the launch of a biosimilar Eylea may not be as bad as the share price performance in the last few weeks leads us to believe, and Regeneron has the broadest late-stage ...

when Eylea biosimilars could launch. That said, the high-dose formulation has generated excellent data that we think will significantly limit pressure from biosimilars of the original Eylea.

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

The judge’s ruling was a surprise, because the same judge has previously granted Regeneron’s request for injunctions against other drugmakers seeking to launch Eylea biosimilars — seemingly ...